2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Docetaxel
6
Gemcitabine
3
Carboplatin
3
lorlatinib
2
cemiplimab
2
Vinorelbine
2
S 1 (combination)
2
Pemetrexed
2
Erlotinib Hydrochloride
2
Cisplatin
2
Cetuximab
2
zimberelimab
1
surufatinib
1
sintilimab
1
quemliclustat
1
pemigatinib
1
pembrolizumab
1
nimotuzumab
1
fludarabine
1
WW Domain-Containing Oxidoreductase
1
Paclitaxel
1
Interleukin-2
1
Gene Expression Profiling
1
Drug Therapy
1
Cyclophosphamide
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Non-Small Cell Lung Cancer
×
zimberelimab
×
Clear all
NCT05676931
2025-10-02
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled